Peritoneal Carcinomatosis Survival Rate
Statistics Relating To The Peritoneal Carcinomatosis Survival Rate
Suffers of cancers in the abdomen are often concerned about the peritoneal carcinomatosis survival rate. This is a condition that is associated with colorectal cancer. Sadly, the prognosis is often rather negative. In the last twenty years, surgery and therapy have been combined to help reduce the rate and speed of mortality in these patients.
Patients are carefully selected for this management regime. This is because the cost, morbidity and mortality are considered to be significant. Patients are put through stringent prognostic tests to see whether they are eligible for the treatment. Studies have been carried out and it is encouraging to note that the patients lived longer with this treatment. It has been found that some patients have been cured by the therapeutic approach as well.
Studies have shown that there is no visible long-term evidence of the disease and this is beneficial to the patients. Collaboration is made possible with other treatment centers to standardize the way in which these patients are treated. It is believed that mortalities will be reduced further once collaboration has been effectively established.
Guidelines and protocols will be in place that will aid oncologists and surgeons to be better equipped to treat these patients more effectively. Researchers from other several countries have found that intraperitoneal chemotherapy coupled with aggressive debulking will decrease the number of mortalities of these patients.
Most patients with this condition will not live much longer than two years without treatment. The shortest time they usually survive is only six months. Treatment for TC, as with other types of cancer, is elective. The options will be explained to the patient, upon which they may decide which is the best option for them.
Reviews were conducted on more than four hundred patients who received this form of therapy. Three hundred and forty-one patients were found to have metastatic cancer, which means that the disease spread from the colon. According to the peritoneal carcinomatosis survival rate statistics, 17% of the patients who received treatment died after surgery.